|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500095717 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-10 17:40:15 |
|
注册时间: Date of Registration: |
2025-01-10 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
Sin1/mTORC2 在流感发病过程中产生抗体的作用及机制研究 |
|
Public title: |
Role and mechanism of Sin1/mTORC2 in influenza |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
Sin1/mTORC2 在流感发病过程中产生抗体的作用及机制研究 |
|
Scientific title: |
Role and mechanism of Sin1/mTORC2 in influenza |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李曼 |
研究负责人: |
李曼 |
|
Applicant: |
Man Li |
Study leader: |
Man Li |
|
申请注册联系人电话: Applicant telephone: |
+86 150 2105 7656 |
研究负责人电话: Study leader's telephone: |
+86 150 2105 7656 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1805234@tongji.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
1805234@tongji.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延长中路301号 |
研究负责人通讯地址: |
上海市静安区延长中路301号 |
|
Applicant address: |
301 Yanchang Middle Road, Jing'an District, Shanghai |
Study leader's address: |
301 Yanchang Middle Road, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第十人民医院 |
||
|
Applicant's institution: |
Shanghai Tenth People's Hospital |
||
|
研究负责人所在单位: |
上海市第十人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Tenth People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SHSY-IEC-4.1/20-91/01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第十人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Tenth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-06-17 00:00:00 |
||
|
伦理委员会联系人: |
袁雪宇 |
||
|
Contact Name of the ethic committee: |
Xueyu Yuan |
||
|
伦理委员会联系地址: |
上海市静安区延长中路301号 |
||
|
Contact Address of the ethic committee: |
301 Yanchang Middle Road, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6630 1604 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市第十人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Tenth People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区延长中路301号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
301 Yanchang Middle Road, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金委 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
Target disease: |
Pulmonary inflammatory disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
通过对比肺部感染患者及健康对照者血液样本中淋巴细胞亚群分析,评估肺部感染患者B淋巴细胞Sin1/mTORC2的活力,对比肺部感染患者血清中炎性因子及细胞因子水平,阐明Sin1/mTORC2在肺部感染疾病发病过程中的作用及相关机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
Respiratory infection disease has been spread worldwide, and adaptive humoral immunity is key component for contributing to recovery from infection. B lymphocytes were regarded as providing protective immunity for proper performance. This study aimed to evaluate B cells subsets in peripheral blood samples and cytokines in serum from patients with pulmonary inflammatory disease, and figure out the role of B cells in pulmonary inflammatory disease. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
患者标准: 1. 年龄18周岁以上; 2. 临床确诊为流感; 3. 无严重心、肺、肝、肾等重要脏器疾病; 4. 依从性好,愿意配合进行样本采集。 健康对照标准: 1. 年龄18周岁以上; 2. 无严重心、肺、肝、肾等重要脏器疾病; 3. 依从性好,愿意配合进行样本采集。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria for patients: 1. Above 18 years old; 2. Patients with clinically confirmed with influenza; 3. No serious heart, liver, kidney and other important organ diseases; 4. Good compliance and willingness to cooperate with sample collection. Inclusion criteria for healthy controls: 1. Above 18 years old; 2. No serious heart, liver, kidney and other important organ diseases; 3. Good compliance and willingness to cooperate with sample collection. |
||||||||||||||||||||||
|
排除标准: |
1. 妊娠或哺乳期妇女; 2. 患者有严重未控制的内科疾病或急性感染者; 3. 患者不能理解研究目的或不同意研究的要求; 4. 不具备法律能力或法律能力受限制; 5. 研究者判断依从性不好,不能配合进行样本采集; 6. 任何病史,据研究者判断可能干扰试验结果或增加患者风险。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant or lactating women; 2. The patient was also accompanied with multiple organ tumors or severe uncontrolled medical disease or acute infection; 3. Patients don't understand the purpose of this study or dont agree with requirements for the study; 4. Patients who lack of legal capacity or limitations of legal capacity; 5. Patients who are not willing to cooperate in sample collection; 6. Patients who have related medical history which could interfere results and increase risk of patients. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-06-12 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-12-10 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan临床试验公共管理平台共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/register.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统(Electronic Data Capture, EDC),ResMan, http://www.medresman.org.cn/login.aspx |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |